A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen.


Journal

Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645

Informations de publication

Date de publication:
02 2019
Historique:
received: 06 06 2018
revised: 24 08 2018
accepted: 26 08 2018
pubmed: 31 8 2018
medline: 10 9 2019
entrez: 31 8 2018
Statut: ppublish

Résumé

The EDITION trials in type 2 diabetes demonstrated comparable glycaemic control with less nocturnal and anytime (24-hour) hypoglycaemia for insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100). However, the predefined nocturnal window (0:00-5:59 AM) may not be the most relevant for clinical practice. This post-hoc analysis compared expansions of the predefined nocturnal interval during basal insulin treatment without prandial insulin. Patient-level, 6-month data, pooled from the EDITION 2 and 3 trials and the EDITION JP 2 trial (N = 1922, basal insulin only) were analysed. Accompanying hypoglycaemia during treatment with Gla-300 was compared to that during treatment with Gla-100, using predefined (0:00-5:59 AM) and expanded (10:00 PM-5:59 AM, 0:00-7:59 AM, 10:00 PM to pre-breakfast SMPG) windows. Confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemic events were reported most frequently between 6:00 AM and 8:00 AM. Windows expanded beyond 6:00 AM included more events than other windows. The percentage of participants with at least one event was lower with Gla-300 than Gla-100 in all windows examined. Expanding the nocturnal interval allows better assessment of the risk of hypoglycaemia associated with basal insulin. The risk of nocturnal hypoglycaemia was consistently lower with Gla-300 versus Gla-100 using all four windows.

Identifiants

pubmed: 30160030
doi: 10.1111/dom.13515
pmc: PMC6586031
doi:

Substances chimiques

Insulin 0
Insulin Glargine 2ZM8CX04RZ

Banques de données

ClinicalTrials.gov
['NCT01499095', 'NCT01676220', 'NCT01689142']

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

402-407

Informations de copyright

© 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Références

Diabetes Care. 2018 Aug;41(8):1672-1680
pubmed: 29895556
Diabetes Educ. 2014 May;40(3):269-279
pubmed: 24695260
Diabetes Obes Metab. 2018 Nov;20(11):2541-2550
pubmed: 29888454
Diabetes Obes Metab. 2016 Apr;18(4):366-74
pubmed: 26662838
Diabetes Care. 2012 Jun;35(6):1364-79
pubmed: 22517736
Diabetes Obes Metab. 2015 Apr;17(4):386-94
pubmed: 25641260
Diabetes Care. 2014 Dec;37(12):3235-43
pubmed: 25193531
Diabetes Metab Res Rev. 2016 Sep;32(6):478-96
pubmed: 26509843
Diabet Med. 2012 May;29(5):682-9
pubmed: 22313123
Diabetes Care. 2014 Oct;37(10):2755-62
pubmed: 25078900
Diabetes Metab. 2018 Sep;44(4):333-340
pubmed: 29277378
Diabetes Care. 2015 Apr;38(4):637-43
pubmed: 25150159
Diabet Med. 2016 Apr;33(4):478-87
pubmed: 26484727
Diabetes Obes Metab. 2019 Feb;21(2):402-407
pubmed: 30160030
Diabetes Care. 2011 Jun;34(6):1312-4
pubmed: 21498786

Auteurs

Geremia B Bolli (GB)

Department of Medicine, University of Perugia, Perugia, Italy.

Carol Wysham (C)

Diabetes and Endocrinology Center, Rockwood Clinic, Spokane, Washington.

Miles Fisher (M)

Glasgow Royal Infirmary, University of Glasgow, Glasgow, UK.

Soazig Chevalier (S)

Sanofi, Paris, France.

Anna M G Cali (AMG)

Sanofi, Paris, France.

Bruno Leroy (B)

Sanofi, Paris, France.

Matthew C Riddle (MC)

Oregon Health and Science University, Portland, Oregon.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH